Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow

• First Year Infection Risk in SLE Patients Treated with Rituximab versus Standar…

SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo. Greatest in those with: 🔹+dsDNA 🔹low C3 or C4 🔹SLICC/ACR Damage index of 0 (argument for early treatment!) https://t.co/UcGXEklqwJ #ACR21 Abst#1295 @RheumNow

• Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple…

Dr. Petri on SLE, Vit D, and BMD ~1k pts, 92% fem, 42% Black, 48% White Freq. of osteoporosis: 💠M ~ F 💠Black ~ White 💠⬆️in smokers Lumbar BMDs showed: 💠Vit D level w/Paradoxical effect 💠Rec goal of 40ng/mL in SLE https://t.co/kBylQAwqhD #ACR21 Abst#1265 #ACRBest @RheumNow

• Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE - ACR Meeting Ab…

#ACR21 #Abstr1462 More case against Low dose Hydroxychloroquine as could ⬆️ risk of #lupus flares. Adjusted risk as below: Weight =>80kg, <400mg/d dose (OR 8.3) Weight <80kg, <300mg/d dose (OR 2.6) @RheumNow https://t.co/bTRMJDoSoI https://t.co/yzopiO3Kbo

• Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares - A…

Post hoc analysis of BLISS-LN 🦋 Pts who didn't receive steroid pulses at induction 👇 🔸⬆ PERR & CRR responders, ⬇mean daily pred doses, more pts had ave daily pred <=5mg or <=7.5mg for both BEL & PBO 🔸BEL grp ⬇ flares/kidney-related death @RheumNow #ACR21 #ACRBest abs1461 https://t.co/ev0LK7d6oL

Dr. Furie asked Dr. Touma what he was doing in 1976? Dr. Touma said, "I was not even in school, yet." Dr. Furie noted that in 1976, the first study was published on methylprednisolone pulse for lupus nephritis in 7 patients. #ACR21 @rheumnow Link below https://t.co/Oe9xmH7Tzg https://t.co/xslAHYNXej

• https://www.sciencedirect.com/science/article/pii/S0140673676912721?via%3Dihub=

#ACR21 #SLE #COVID19 Use of Telemedicine for follow-up of SLE in COVID19 Wait times lower for telemedicine Patient satisfaction higher in telemedicine group More hospitalization, higher switch to in person follow up in telemedicine https://t.co/Y21Vki1uDP

#ACR21 #SLE SLE – Treatment: New Agents, Old Agents Pooled data from 2 phase 3 trials (TULIP 1 and 2) ⏬LLDAS is an attainable T2T endpoint in adult SLE trials ⏬Anifrolumab treatment associated with earlier and more sustained LLDAS in adult SLE https://t.co/bxGlVsJOZC

👉HCQ dose < 400 mg/d are assc with SLE flare. Lower doses of HCQ may decrease risk of retinopathy. 👉For >80 kg (176 lbs), any dose < 400 mg/day is assc with increased odds of flare (HCQ blood levels not measured) Abst#1462 #ACR21 @rheumnow https://t.co/5tx3kruT8W